HiDAC

Phase 3Small molecule

Pfizer

HiDAC is one of 63 small molecule programs targeting Acute Lymphoblastic Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Lymphoblastic LeukemiaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Acute Myeloid LeukemiasActive, not recruiting

Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

Acute Myeloid LeukemiaPhase 1

Active, not recruiting

Acute Myeloid LeukemiasPhase 1

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Phase 3

28 2

Empaveli

Gilead

Phase 3

4 3

Oblimersen Sodium

NNational Cancer Institute (NCI)

Phase 3

3 4

GM-CSF

YY-mAbs Therapeutics

Phase 3

1 5

Sapacitabine

CCyclacel Pharmaceuticals, Inc.

Phase 3

1 6

APG-2575

Ascentage Pharma Group Inc.

Phase 3

1 7

Recombinant FLT3 Ligand

EEastern Cooperative Oncology Group

Phase 3

1 8

Low-Dose Cytarabine

Bristol-Myers Squibb

Phase 3

2 9

Daunorubicin or Idarubicin

Novartis

Phase 3

1 10

HiDAC

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Acute Myeloid Leukemias

NCT06226571

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia1 trial

A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Completed· Pfizer logo

Pfizer·Phase 3·NCT01564784·326 enrolled

Acute Myeloid Leukemias1 trial

A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes

Active, not recruiting·SSyndax Pharmaceuticals·Phase 1·NCT06226571·76 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for HiDAC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HiDAC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HiDAC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

HiDAC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Acute Lymphoblastic Leukemia1 trial

Acute Myeloid Leukemias1 trial

References

Drug Info

Quick Facts

Related News